Bellini Massimo, Berti Ginevra, Bonfrate Leonilde, Ciranni Flavia, Di Ciaula Agostino, Di Ruscio Mirko, Dell'Era Alessandra, Lambiase Christian, Noto Antonino, Pancetti Andrea, Portincasa Piero, Rettura Francesco
Gastrointestinal Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Clinica Medica A. Murri, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro Medical School, Bari, Italy.
Patient Prefer Adherence. 2021 Aug 13;15:1763-1774. doi: 10.2147/PPA.S318859. eCollection 2021.
Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by recurrent chronic abdominal pain and impaired bowel habits, which affects daily activity and work productivity, and is associated with a significant healthcare economic burden as well as an impaired quality of life and psycho-affective profile. Management of patients is a great challenge for physicians; at the present, the therapeutic strategy aimed to treat the different symptoms, and no medical therapy is proven to modify the natural history of the disease. GELSECTAN (xyloglucan, pea protein and tannins, xylo-oligosaccharides) is a medical device with both protective and prebiotic actions on the intestinal mucosa, able to restore intestinal permeability and to improve gastrointestinal symptoms, controlling diarrhoea, abdominal pain and bloating in adult patients with irritable bowel syndrome. We report and discuss four cases of different patients with irritable bowel syndrome successfully managed with Gelsectan in the real clinical practice. Literature data, as well as these case reports, show that this device is effective and safe in improving symptoms and bowel habits associated to irritable bowel syndrome; its efficacy and safety were confirmed for the long-term use too. Agents with film-forming protective properties, such as Gelsectan, represent a new alternative therapeutic option for the management of patients with irritable bowel syndrome.
肠易激综合征是一种慢性功能性胃肠疾病，其特征为反复出现的慢性腹痛和排便习惯改变，这会影响日常活动和工作效率，并带来巨大的医疗经济负担，同时导致生活质量下降和心理情感问题。对医生而言，患者的管理是一项巨大挑战；目前，治疗策略旨在缓解不同症状，尚无药物疗法被证实可改变该病的自然病程。GELSECTAN（木葡聚糖、豌豆蛋白和单宁、木寡糖）是一种对肠黏膜具有保护和益生元作用的医疗器械，能够恢复肠道通透性并改善胃肠道症状，可控制成年肠易激综合征患者的腹泻、腹痛和腹胀。我们报告并讨论了在实际临床实践中使用Gelsectan成功治疗的4例不同肠易激综合征患者。文献数据以及这些病例报告表明，该器械在改善与肠易激综合征相关的症状和排便习惯方面有效且安全；其长期使用的有效性和安全性也得到了证实。具有成膜保护特性的制剂，如Gelsectan，为肠易激综合征患者的管理提供了一种新的替代治疗选择。
